Introduction The role of erythrocytes in the acute coronary syndrome (ACS) is complex. The
aim of this review in terms of PICO (P: patients; I: intervention; C: comparison; O: outcome) …

In the recent past, substantial advances have been made in the treatment of myocardial
infarction (MI). Despite the impact of these positive developments, MI remains to be a …

Recent studies have shown that high-risk patients with type 2 diabetes mellitus (T2DM)
treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have improved …

Neuroprotective drugs to protect the brain against cerebral ischemia and reperfusion (I/R)
injury are urgently needed. Mammalian cell-produced recombinant human erythropoietin …

Background Erythropoietin (EPO) has been suggested to promote cardiac repair after MI.
However, the randomized, double-blind, placebo controlled REVIVAL-3 trial showed that …

Erythropoietin (EPO) has been shown to protect the heart against acute myocardial
infarction in pre-clinical studies, however, EPO failed to reduce infarct size in clinical trials …

Myocardial infarction (MI) is a global cause of morbidity and mortality. MI is the outcome of a
chronic process termed atherosclerosis, a buildup of fatty and other substances called …

Cyclic helix B peptide (CHBP) is a peptide derivant of erythropoietin with powerful tissue-
protective efficacies in a variety of organ injuries, but without erythropoietic effect. However …

The association between alcohol consumption and the risk of subarachnoid hemorrhage
(SAH) is inconsistent. Thus, meta‑and a dose-response analyses are presented with the …

Objective: Erythropoietin (EPO) for treating acute ischemic stroke (AIS) has been
investigated in many studies. However, the evidence was inconsistent. Thus, a systematic …